The facilities in France and Singapore were recognized for their modular, scalable, AI-enabled design, producing multiple vaccine platforms and biologics simultaneously.
The technology transfer will prepare S2N.Bio’s autologous cell therapy for clinical manufacturing ahead of a planned first-in-human trial in 2027 in that country.
The integrated systems are designed to consolidate packaging operations that might otherwise require separate equipment for printing, verification, and sealing.
